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intraluminal treatment with VEGF is benefi cial to the 
healing process in vascular microsurgery. Osteopontin 
and TGF-  1 , both induced by VEGF, may play an impor-
tant role in the vascular remodeling process. Our results 
provide clear evidence that VEGF application may repre-
sent a useful strategy in accelerating reendothelializa-
tion and improving vascular healing after microsur-
gery. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The loss of endothelium as occurs after vascular trau-
ma, microvascular transplantation, and replantation in 
reconstructive surgery is associated with increased throm-
bosis, smooth muscle cell (SMC) proliferation and neo-
intimal formation, processes that often lead to stenosis 
and vessel occlusion. It is clinically important to achieve 
fast and perfect regeneration of the endothelial cell layer 
after microvascular anastomosis to increase the survival 
of replanted or transplantated tissue. 
 The kinetics of reendothelialization (rET) after micro-
anastomosis of vessels are not completely understood. 
Vascular endothelial growth factor (VEGF) is one of the 
most potent mediators of vascular regulation in angiogen-
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 Abstract 
 Background: Early reconstitution after injury to the en-
dothelium is an important feature for reducing a number 
of vessel wall pathologies. We investigated the effect of 
vascular endothelial growth factor (VEGF) and its impact 
on the vascular remodeling process and reendothelial-
ization after microsurgery.  Methods and Results: Micro-
vascular anastomosis was performed in the rat femoral 
artery. One group was treated with intraluminal admin-
istration of VEGF and the other with vehicle. We investi-
gated morphological, ultrastructural and immunohisto-
chemical changes of the vascular wall and the 
reendothelialization process. After 10 days, reendothe-
lialization was signifi cantly faster in VEGF-treated rats. 
Transmission electron microscopy revealed a complete 
healing in contrast to vehicle-treated vessels. Moreover, 
extracellular matrix proteins, such as fi bronectin, colla-
gen types I, III and IV, were signifi cantly increased. Fur-
thermore, VEGF treatment signifi cantly induced VEGF 
receptor 2, fl k-1, osteopontin and TGF-  1  proteins.  Con-
clusions: Our data clearly document for the fi rst time that 
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esis and vascular permeability  [1–4] . VEGF, also called 
‘vascular permeability factor’, is an endothelial cell-spe-
cifi c mitogen secreted as a 45-kDa protein that consists 
of two subunits which does not induce cell proliferation 
of other cell types. There exist fi ve human isoforms with 
different numbers of amino acids (VEGF 121, 145, 165, 
189, 206), generated by alternative splicing of the mRNA 
from a single gene comprising eight exons  [2] . VEGF 121 
and VEGF 165 are the only soluble isoforms and are the 
most abundant ones. VEGF 165 is the most powerful 
stimulator of endothelial cell proliferation  [5] . VEGF 121 
is responsible for the increase in vascular permeability 
 [6] . To date, fi ve different members of the VEGF family 
have been discovered: VEGF-A (165), VEGF-B, VEGF-
C, VEGF-D and VEGF-E. Only VEGF-A, VEGF-B, and 
VEGF-E modulate vascular angiogenesis and permeabil-
ity. VEGF-C and VEGF-D modulate lymphatic angio-
genesis. In addition to its mitogenic effect, VEGF has 
been shown to increase the permeability of the periph-
eral circulation and endothelial cell monolayers  [5, 6] . 
The major factor seems to be VEGF, referred to also as 
VEGF-A. The expression of VEGF is controlled by dif-
ferentiation, transformation, and oxygen supply. The ef-
fect of VEGF is regulated by two receptor tyrosine ki-
nases, VEGFR-1/fl t-1 and VEGFR-2/fl k-1/KDR, which 
are almost exclusively located on endothelial cells.  
 The aim of this study was (1) to measure if local VEGF 
application can improve rET after microanastomosis and 
(2) to investigate the impact of VEGF on the vascular re-
modeling process in vessels with or without VEGF treat-
ment.  
 Materials and Methods 
 Animal Grouping 
 Adult male Sprague-Dawley rats (body weight 250–300 g) were 
obtained from Charles River Wiga (Sulzfeld, Germany). They were 
maintained on standard rat chow (H1003, Alma KG, Kempten, 
Germany) with water ad libitum. All animals were individually 
housed in a 12-hour dark/light cycle-controlled room. The proto-
cols were approved by the local standing committee on animal re-
search. The investigation conforms with the ‘Guide for the Care 
and Use of Laboratory Animals’ published by the US National In-
stitutes of Health (NIH Publication No. 85-23; revised 1985). A 
total of 40 rats were randomized to VEGF (10 ng/ml)  [7] or vehicle 
(saline) treatment. The following groups were investigated: (1) day 
0: rats were sacrifi ced at 10 min after local VEGF or vehicle appli-
cation (n = 5, each group); (2) 10 rats were sacrifi ced at day 5 for 
histological examination (n = 5, each group), and (3) rats were sac-
rifi ced at day 10 (n = 10, each group). At each time point 2 vessels 
were collected (left femoral artery with anastomosis and right fem-
oral artery without anastomosis). 
 Surgical Procedure 
 Rats were anesthetized by intraperitoneal application of thio-
pental sodium (100 mg/kg, i.p.)  [8] . The skin over the femoral artery 
was shaved, swabbed with povidone-iodine solution, and incised. 
Using a surgical microscope (Zeiss, Oberkochen, Germany), micro-
surgical preparation of the nerve vessel sheath was performed. A 
segment of the left femoral artery was carefully dissected from sur-
rounding tissues. A pair of microclamps (Acland, S + T Germany) 
was used. To interrupt blood fl ow, the vessel was sharply transect-
ed at the middle of the segment. After stripping of the adventitia 
and fl ushing of the lumen with heparinized saline (1/10,000), a di-
rect end-to-end repair was performed with Nylon 11/0 sutures ( fi g. 
1 A) with about 10 sutures (diameter of vessel: 0.6–1 mm). After the 
anastomosis ( fi g. 1 A–C) was performed, one group was treated with 
intraluminal (via anastomosis) application of recombinant rat 
VEGF 164 (Sigma, Deisenhofen, Germany) for 10 min (10 ng/ml) 
by clamping. The other group was treated with vehicle for 10 min 
(saline). Subsequently, the clamp was removed. Perfusion was test-
ed with two forceps by occluding the vessel distal to the anastomo-
sis site with one pair of forceps. A short segment of the vessel distal 
to the fi rst pair was emptied with a second pair of forceps closed, 
the proximal pair was released and it was noted whether and how 
fast the emptied segment of the vessel refi lled. Immediate refi lling 
indicated patency of the anastomosis site, slow refi lling suggested 
vessel spasm, partial thrombosis, or technical error, and no refi lling 
indicated thrombosis or severe technical error. After perfusion of 
the anastomosis, the skin was closed with 3/0 Nylon sutures. 
 During surgery, a warming lamp was used to maintain the body 
temperature at 37  °  C until the animal recovered from anesthesia. 
All surgical procedures were performed by an experienced plastic 
microsurgeon.  
 Follow-Up 
 After 10 min or 5 or 10 days, the vehicle or VEGF-treated rats 
were sacrifi ced and the vessels (left femoral artery with anastomosis 
and right femoral artery without anastomosis) were excised for his-
tological ( fi g. 1 B, C), electron-microscopic, immunohistochemical, 
and Western blot analyses. 
 Transmission Electron Microscopy 
 Transmission electron microscopy followed routine protocols 
according to Shakibaei et al.  [9] . After fi xation and postfi xation in 
1% tannic acid (0.1  M phosphate buffer) and 1% OsO 4  solution 
(0.1  M phosphate buffer), the vessel was dehydrated in an ascend-
ing alcohol series. The samples were embedded in Epon and cut on 
a Reichert Ultracut (Reichert-Jung, Nussloch, Germany), which 
was followed by administration of 2% uranyl acetate/lead citrate 
for contrast. The vessels were examined using a transmission elec-
tron microscope (TEM 10, Zeiss).  
 Histological Evaluation and Polarization Microscopy 
 For histology, transverse   tissue slices of one part of the vessels 
(n = 5, each group, day 5) were cut at 2–3 mm away from the anas-
tomosis and subjected to hematoxylin-eosin and Sirius red staining 
as a specifi c dye for connective tissue structures. The slices were 
immersed in Dubosq-Brasil solution,   embedded in paraffi n, and cut 
into 3-  m sections. Standardized staining was realized using a Ro-
bot-Stainer system (Robot-Stainer HMS 760, Microm   GmbH). The 
amount of    fi brosis was quantifi ed after Sirius red staining by mor-
phometry. Fibrosis was visualized using a Zeiss Axiophot micro-
 Infanger et al. 
 
 J Vasc Res 2005;42:202–213 204
scope (Zeiss). Stenosis, thrombosis, rET, intimal hyperplasia, vas-
cular structure, and aneurysm formation of the anastomosis site 
were documented. Polarization microscopy was performed accord-
ing to Junqueira et al.  [10] . Collagen type I presents a yellow, orange 
or red color, while collagen type III appears green. 
 Immunohistochemical Staining 
 The structural changes of the vessels at day 5 (n = 5, each group) 
were investigated using light microscopy (Olympus Optical, Ham-
burg, Germany). Frozen specimens were sectioned at 3   m and 
fi xed with acetone (–20  °  C) for 10 min. Sections were selected to 
visualize antigen-antibody complexes using the indirect peroxidase 
technique. Incubation with the fi rst antibody (osteopontin, 
MPIIIB10 1 , University of Iowa, Hybridoma Bank, USA) was fol-
lowed by incubation with a peroxidase-labeled second antibody. 
After repeated washing with phosphate-buffered saline, the slices 
were exposed to diaminobenzidine and H 2 O 2 , generating a brown 
color. Finally, the  specimens were dehydrated and embedded with 
Entellan  (Merck, Darmstadt, Germany). Controls for the antibody 
staining were negative.  
 Quantitative Image Analysis 
 The measurements of the arteries were performed using a video 
camera combined with a separated video   control system (Sony MC-
3255, AVT-Horn GmbH) adapted   to a Zeiss Axiophot microscope. 
Image analysis was performed   with the use of freely available soft-
ware (Scion Image 1.62a, Scion Co.) on a Power Macintosh 
8200/120 computer. The magnifi cation was 10-fold. Multiple sec-
tions (n = 10) were examined for each specimen. The total, luminal, 
and medial vessel areas (  m²) were measured. The media thickness 
was measured and the media-fi brosis-to-lumen ratio as well as me-
dia-to-lumen ratio were calculated.  
 For quantitative image analysis of osteopontin, the samples 
were digitalized, gray-scale   images were transformed into binary 
images, and the relation of the osteopontin-immunostained area to 
the total luminal area   of the vessel was determined. 
 Western Blot Analysis  
 Western blot analyses were performed at day 0 and 10 and 
 carried   out   following   routine   protocols   [11] . Antibodies against 
the following antigens were used for this study: VEGF-A, fl k-1, 
TGF-  1 , collagen types I and IV (Santa Cruz, Santa Cruz, Calif., 
USA), fi bronectin (Chemicon, Hofheim, Germany), collagen type 
III (Monosan, Beutelsbach, Germany), and osteopontin (MPIIIB10 1 , 
University of Iowa, Hybridoma Bank, USA). 
 SDS-PAGE and immunoblotting were carried out following 
routine protocols  [11] . The samples were homogenized by shearing 
forces in lysis buffer (50 m M Tris-HCl, pH 7.2; 150 m M NaCl; 1% 
Triton X-100; 1 m M sodium orthovanadate; 50 m M sodium pyro-
phosphate; 100 m M sodium fl uoride; 0.01% aprotinin; 4   g/ml 
 Fig. 1.  A Microsurgery of the rat femoral artery. The anas-
tomosis (arrow) is seen between two Acland clamps. 
 B Polarization microscopy of a longitudinal section from an 
anastomosed femoral artery (arrow: sutures). Collagen type 
I (yellow, orange, red) using Sirius red staining according to 
Junqueira et al.  [10] is detectable.  C Longitudinal sections of 
the vessel to demonstrate the anastomosis (arrow: suture). 
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pepstatin A; 10   g/ml leupeptin, and 1 m M phenylmethylsulfonyl 
fl uoride) on ice for 30 min. For immunoblotting, equal amounts of 
total proteins (50   g total protein, each fraction was loaded per 
lane) were separated on 7.5% SDS-PAGE polyacrylamide gels un-
der reducing conditions. 
 Subsequently, the homogenates were transferred onto a nitrocel-
lulose membrane (Schleicher & Schuell, Dassel, Germany) using a 
Transblot electrophoresis apparatus (Mini Trans Blot, Bio-Rad Lab-
oratories, Richmond, Calif., USA) for 1 h at 120 V. Membranes were 
blocked with 5% (wt/vol) skim milk powder in PBS/0.1% Tween 20 
overnight at 4  °  C and incubated with primary antibodies diluted in 
blocking buffer for 1 h at room temperature. After fi ve washes in 
blocking buffer, membranes were incubated with alkaline phospha-
tase-conjugated secondary antibody diluted in blocking buffer for 
30 min at room temperature. Membranes were fi nally washed 5 times 
in blocking buffer and 3 times in 0.1  M Tris (pH 9.5) containing 
0.05  M MgCl 2  and 0.1  M NaCl; specifi c binding was detected using 
nitroblue tetrazolium and 5-bromo-4-chloro-3-indoyl-phosphate ( p -
toluidine salt; Pierce, Rockford, Ill., USA) as substrates and was mea-
sured by densitometry (Personal Densitometer 50301, Molecular Dy-
namics, Krefeld, Germany). Protein determination was performed 
with the bicinchoninic acid system using BSA as a standard  [11] . 
 Statistical Analysis 
 Statistical analysis was performed using SPSS 10.0. Results are 
expressed as mean  8 SEM. Comparisons between multiple groups 
were assessed by one-way analysis of variance (ANOVA), including 
a modifi ed least-signifi cant difference (Bonferroni) multiple-range 
test to detect signifi cant differences between two distinct groups, 
which were further analyzed using the Mann-Whitney U test. The 
strength of the relationship between two variables was assessed by 
calculation of the product-moment correlation coeffi cient (r). Sta-
tistical signifi cance was accepted at the level of p  ! 0.05.  
 Results 
 Patency Rate 
 The forceps vessel fl ow test showed a 100% patency 
rate in all surgery groups immediately after anastomosis. 
One vessel of the vehicle-treated animals was occluded 
by a thrombus. 
 Effect of VEGF on Survival Rate 
 All VEGF-treated animals with microsurgery survived 
the entire 10 days’ observation period. In contrast, 2 rats 
of the vehicle-treated animals died. One animal died at 
day 2 because of hypovolemia due to bleeding because of 
a defect at the anastomosis, the other at day 8 because of 
pneumonia. Both deaths were not related to treatment. 
 VEGF Enhances rET 
 Transmission electron microscopy revealed a com-
plete rET and healing at day 10 postsurgery in VEGF-
treated vessels ( fi g. 2 B). Vehicle-treated vessels exhibited 
defective healing, as shown in  fi gure 2 C. 
 Investigation of Collagen and Osteopontin 
 As osteopontin is involved in collagen organization, 
we analyzed the expression of collagen in vessels with and 
without anastomosis. Using Sirius red staining accord-
ing to Junqueira et al.  [10] , a clear increase in collagen 
 Fig. 2. Electron microscopy of the rat femoral artery.  A Control, normal basement membrane (arrow) of a control 
microvessel.  B Anastomosis of the microvessel with local administration of VEGF. After 10 days, the basement 
membrane defect is closed (arrow), healing is perceptible and rET is clearly detectable.  C Anastomosis of the mi-
crovessel with vehicle administration. After 10 days, defect healing was noted, the basement membrane remained 
open (arrow).  A – C Magnifi cation  ! 4,000. 
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type I was detectable in the perivascular space ( fi g. 3 C, 
D) at day 5 postsurgery in vehicle-treated vessels with an 
anastomosis compared to the corresponding control 
group ( fi g. 3 A, B). Intraluminal VEGF application in-
duced an increase in collagen type III in the control vessel 
( fi g. 3 E, F) and an enormous accumulation in the vessels 
with anastomosis ( fi g. 3 G, H). Collagen type I was also 
detectable in reanastomosed vessels (yellow, orange and 
red staining). The percentage of media fi brosis-to-lumen 
ratio is given in  fi gure 3 I. At day 5, VEGF signifi cantly 
increased media fi brosis in vessels with and without anas-
tomosis. The media-to-lumen ratio is clearly elevated in 
VEGF-treated vessels with anastomosis ( fi g. 3 J). 
 Osteopontin was increased in the media in VEGF-
treated vessels compared to the corresponding controls 
( fi g. 4 A–D). Quantitative image analysis revealed a clear 
increase of osteopontin in VEGF-treated vessels with and 
without anastomosis ( fi g. 4 E). 
 Effect of VEGF on VEGF-A and Flk-1 Protein 
 Anastomosis.  VEGF protein at day 0 was decreased as 
compared to the group without anastomosis. Restoration 
of VEGF expression at day 10 to control level is detect-
able. Application of VEGF induced VEGF-A protein im-
mediately after surgery and it reached the highest level at 
10 days after intervention ( fi g. 5 A). 
 Flk-1 protein was reduced at day 0 in the anastomosed 
vessel and then clearly elevated at 10 days after surgery. 
VEGF induced the VEGF receptor after 10 min to the 
same level that was reached after 10 days with and with-
out VEGF ( fi g. 5 B). 
 Fig. 3. Sirius red staining at day 5 postsurgery.  A Control 
vessel of a vehicle-treated rat.  B Polarization microscopy of 
the same section. Only little collagen type I (orange)- and III 
(green)-positive material is seen.  C ,  D Vehicle-treated re-
anastomosed vessel with perivascular fi brosis. Polarization 
light revealed a clear accumulation of collagen type I (yellow, 
orange and red) as well as collagen type III (green).  E ,  F Con-
trol vessel of a VEGF-treated animal. Polarization micro-
scopic examination revealed a clear increase of collagen type 
III in the control vessel.  G ,  H The anastomosed VEGF-treat-
ed vessel showed perivascular fi brosis and a striking accu-
mulation of mainly collagen type III (green) compared to 
collagen type I (yellow, orange and red).  I ,  J The data of 
quantitative image analysis are given.  I At day 5 postsurgery, 
VEGF signifi cantly increased the percentage of media fi bro-
sis in vessels with and without anastomosis.  J Media thick-
ness is signifi cantly increased in VEGF-treated vessels with 
anastomosis. 
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 Control Vessel.  VEGF protein content at days 0 and 
10 with and without VEGF application was not signifi -
cantly different. VEGF slightly increased the amount of 
VEGF protein at days 0 and 10 ( fi g. 5 A). There was no 
change in fl k-1 between the control and treated vessel ( fi g. 
5 B). 
 Impact of VEGF on the Extracellular Matrix 
 Anastomosis.  TGF-  1  was increased at day 10 after 
surgery and this increase was more pronounced at day 10 
in VEGF-treated rats. In addition, VEGF treatment re-
sulted in immediate induction of TGF-  1  10 min after 
surgery ( fi g. 5 C). 
 Control Vessel . VEGF signifi cantly increased TGF-  1  
at day 0 and day 10. TGF-  1  on day 10 was similar to day 
0 ( fi g. 5 C). 
 Anastomosis.  Osteopontin was signifi cantly increased 
at 10 days after the surgery. VEGF treatment signifi cant-
ly enhanced osteopontin protein expression early after 
surgery and at day 10 ( fi g. 5 D). 
 Control Vessel.  Osteopontin was elevated in all VEGF-
treated rats ( fi g. 5 D). 
 Anastomosis. Collagen types I and III were clearly el-
evated at day 10 in VEGF-treated rats. At day 0, there 
was no signifi cant difference compared to vehicle-treated 
vessels ( fi g. 6 A, B). Collagen type IV was slightly elevated 
at day 10 in VEGF-treated animals ( fi g. 6 C). VEGF sig-
nifi cantly increased fi bronectin at day 10 postsurgery. 
Moreover, there was a signifi cant increase in fi bronectin 
between day 0 and 10 ( fi g. 6 D). 
 Control Vessel.  Collagen types I and III were signifi -
cantly increased at day 10 in VEGF-treated animals ( fi g. 
6 A, B). Collagen type IV was unchanged in all control 
groups ( fi g. 6 C). On day 10, fi bronectin was slightly, but 
not signifi cantly elevated in vessels exposed to VEGF or 
vehicle ( fi g. 6 D). 
 Discussion 
 VEGF, also known as vascular permeability factor, ex-
erts its biological activity predominantly on endothelial 
cells. It has been shown to be an endothelial cell-specifi c 
mitogen in vitro and to be a key mediator of angiogenesis 
in vivo  [12, 13] . Moreover, our group has recently dem-
onstrated that the VEGF serum level is correlated with 
tissue edema after burn injury  [14] . Recent studies have 
shown that VEGF mRNA and protein are widely distrib-
 Fig. 4. Osteopontin staining, indirect immunoperoxidase method.  A VEGF-treated control vessel.  B VEGF-treat-
ed vessel with anastomosis. Osteopontin is detectable in the intima and media and mainly in the perivascular area 
of the femoral artery.  C Vehicle-treated vessel.  D Vehicle-treated vessel with perivascular fi brosis but with a low-
er amount of osteopontin at day 5 postsurgery.  E Quantitative image analysis of osteopontin: osteopontin is sig-
nifi cantly increased in all VEGF-treated vessels with and without anastomosis. 
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 Fig. 5. Western blot analyses of VEGF ( A ) and the VEGF receptor 
2 (fl k-1) ( B ). The data for the control vessel (right femoral artery 
without anastomosis) and the left femoral artery with anastomosis 
are given.  A The VEGF-treated microvessels exhibited a higher 
amount of VEGF protein as compared to the corresponding vehi-
cle-treated groups.  B VEGF receptor 2 (fl k-1) is immediately up-
regulated after microsurgery in VEGF-treated vessels at day 0. At 
day 10 postsurgery, fl k-1 is increased in both anastomosed groups 
as compared to the vehicle-treated control group at day 0.  Bars 
represent mean  8 SEM. Western blot analyses of TGF-  1  ( C ) and 
osteopontin ( D ). The data for the control vessel (right femoral artery 
without anastomosis) and the left femoral artery with anastomosis 
are given.  C  TGF-  1  is early increased by topical VEGF adminis-
tration in both the anastomosed vessel and the control vessel groups 
at days 0 and 10. Moreover, TGF-  1  protein is clearly elevated at 
day 10 in vehicle-treated vessels with anastomosis as compared to 
the day 0 group.  D Osteopontin is early increased by topical VEGF 
administration in both the anastomosed vessel and the control ves-
sel groups at days 0 and 10. Moreover, osteopontin protein is clear-
ly elevated at day 10 in vehicle-treated vessels with anastomosis as 
compared to the day 0 group. Bars represent mean  8 SEM.  
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uted in normal rat tissues and organs supporting the con-
cept that VEGF may play an important role in the main-
tenance and control of vascular function  [15, 16] . It has 
been shown that in arterial reconstruction procedures us-
ing venous conduits, VEGF is signifi cantly increased at 
48 h in the vein graft and arterial anastomosis. VEGF 
expression in the vein graft normalizes within 4 weeks, 
but remains signifi cantly elevated in the adjacent arterial 
segment. Increased VEGF production after arterial graft-
ing can facilitate rET, thus partially accounting for opti-
mal patency rates achieved with autologous vein grafts 
 [17] . 
 Our data provide the fi rst comprehensive analysis of 
the effect of VEGF on arterial rET and vascular remodel-
ing after microanastomosis. The exact mechanisms in-
volved in the regulation of vascular remodeling after arte-
 Fig. 6. Western blot analyses of collagen type I ( A ), collagen type 
III ( B ), collagen type IV ( C ) and fi bronectin protein ( D ). The data 
for the control vessel (right femoral artery without anastomosis) 
and the left femoral artery with anastomosis are given.  A Collagen 
type I is increased by VEGF application in vessels with and without 
anastomosis at day 10 postsurgery.  B Collagen type III is clearly 
elevated by VEGF administration at day 10 postsurgery.  C Colla-
gen type IV is slightly but not signifi cantly increased at day 10 post-
surgery.  D Fibronectin protein is increased at day 10 compared to 
day 0 in vessels with anastomosis. In addition, topical VEGF ap-
plication increased fi bronectin at day 10 postsurgery. Bars repre-
sent mean  8 SEM.  
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rial injury are poorly understood. Here, we demonstrate 
that VEGF is signifi cantly induced in vascular anastomo-
sis of rat femoral arteries 10 days postsurgery. Since 
VEGF-specifi c receptor fl k-1 is expressed in rat femoral 
arteries and clearly upregulated at day 10 postinterven-
tion, we hypothesized that local application of VEGF af-
ter vascular injury would promote the vascular remodel-
ing process in healing the wounded area. Moreover, we 
detected a decrease in VEGF/fl k-1 protein expression at 
day 0 in vehicle-treated animals with anastomosis. This 
might be explained by the denudation of the vessel be-
cause endothelial cells express VEGF and fl k-1. Restora-
tion to control levels was achieved after healing at day 10. 
In addition, at day 0 in VEGF-treated vessels with anas-
tomosis, the amount of VEGF protein is comparable to 
the control vessel without surgery. This might be ex-
plained by an upregulation of VEGF protein in the re-
maining endothelial cells. In VEGF-treated rats, we de-
tected complete healing 5 days postsurgery and the vas-
cular remodeling process was completely fi nished in 
VEGF-treated animals. Previous investigations on the ef-
fi cacy of VEGF to promote rET after arterial balloon an-
gioplasty have been published  [18, 19] reporting contro-
versial data. Asahara et al.  [18] showed that arterial gene 
transfer of phVEGF165 can accelerate rET at local and 
remote sites, leading to neointimal thickening and reduc-
tion in thrombogenicity. In contrast, Lindner and Reidy 
 [19] reported on a lack of increased endothelial regrowth 
in response to VEGF. Moreover, in a second study they 
demonstrated that vascular SMCs express functional fl t-1 
receptors after arterial injury and that VEGF has syner-
gistic effects with FGF-2 on SMC proliferation in vivo 
 [20] . These effects are likely to be mediated by a VEGF-
mediated increase in permeability as well as a direct in-
teraction between the VEGF and FGF signaling path-
ways. Our fi ndings are in agreement with the fi ndings of 
Asahara et al.  [18] who used another experimental setting, 
the rabbit model of balloon angioplasty. 
 It is well known that mechanical injury induces a wave 
of endothelial proliferation  [20] . The time course was de-
scribed by Schwartz and Benditt  [21] who found no ap-
parent proliferation until 20–24 h after balloon injury, 
but a peak proliferation at 48 h and a decreased prolif-
eration rate at 96 h. Moreover, an infusion of VEGF for 
3 min immediately after endothelial denudation by bal-
loon injury increased endothelial cell proliferation in the 
vascular wall  [22] . 
 A recent publication by Gennaro et al.  [23] describing 
a study in old rabbits demonstrated that an adenoviral 
strategy with a vector encoding for VEGF 165  can signifi -
cantly elevate VEGF expression in injured arteries, ac-
celerate rET and reduce neointimal formation. More-
over, a single topical application of VEGF reduced inti-
mal hyperplasia and improved endothelial function in a 
rabbit vein graft model  [24] . 
 Effects of VEGF on Microvascular Remodeling 
 The healing process of the vessel after trauma is pre-
dominantly dependent on the existence and connection 
of extracellular matrix proteins, such as collagens. Sev-
eral collagens are necessary for the composition of the 
vascular wall and form up to 80% of the dry weight of 
blood vessels  [25] . The vessels mainly contain collagen 
type I and III  [26] . Collagen type I is mainly identifi ed in 
the adventitia and collagen type III preferentially in the 
intima and media  [27] . Collagen IV and laminin can be 
detected in basement membranes which are present in all 
epithelial and endothelial linings and also in muscles and 
nerves. Immunohistochemistry can visualize collagen IV 
and laminin in the subendothelial basement membrane 
and that surrounding vascular SMCs  [28] . This subendo-
thelial basement membrane is necessary for the rET pro-
cess of denuded vessels. Friedrich et al.  [28]  detected col-
lagen type III and IV in experimental microsurgical anas-
tomoses of rat arteries. Collagen IV was distributed in a 
net-like pattern in the media, collagen type III was de-
tected in the adventitia. We detected a few positive col-
lagen type III fi bers in normal vehicle-treated vessels. 
VEGF clearly increased the amount of collagen type III 
in the adventitia of a normal vessel. In vessels with anas-
tomosis an impressing increase of collagen type I is de-
tectable in the media and adventitia. Until today, no data 
exist concerning the impact of VEGF on the expression 
of extracellular matrix proteins in vascular wound heal-
ing. Here, we demonstrate for the fi rst time that VEGF 
signifi cantly increases several collagen types as well as fi -
bronectin. In contrast to untreated anastomosed vessels, 
VEGF-treated vessels exerted a clear accumulation of col-
lagen type III in the media and adventitia. A recent paper 
showed that VEGF induced fi bronectin secretion by cul-
tured human airway SMCs  [7] . Our group has shown in 
a recent study  [29] that inhibition of VEGF activity by 
PTK787/ZK222584, a specifi c blocker of both VEGF re-
ceptor tyrosine kinases, inhibits the growth of a poorly 
differentiated thyroid cancer when using a nude mouse 
xenograft tumor model. Extracellular matrix proteins are 
upregulated in different tumor xenografts, whereas tyro-
sine kinase inhibition signifi cantly reduced the abun-
dance of these extracellular matrix proteins in the inter-
stitial space as well as the perivascular areas  [29] . The 
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mechanisms for these data are still unclear, but an in-
crease in programmed cell death of the tumor cells is dis-
cussed. 
 Furthermore, we detected an increase of TGF-  1  in 
VEGF-treated animals immediately at day 10 after re-
anastomosis. These data suggest that VEGF may play a 
role in stimulating vascular remodeling after vascular in-
jury, either alone or through interactions with other 
growth factors that stimulate the expression of extracel-
lular matrix proteins. TGF-  1  is also increased in the vas-
cular wall in response to balloon injury  [30] . 
 A very interesting and new fi nding is the early upregu-
lation of osteopontin after vascular injury. Osteopontin 
is further elevated in VEGF-treated rats indicating a spe-
cifi c role of this cell adhesion molecule in wound healing 
and early vascular remodeling. Osteopontin is known to 
be a mediator of growth and the cytokine/extracellular 
matrix protein osteopontin (Eta-1) is an important com-
ponent of cellular immunity and infl ammation. It also 
acts as a survival, cell-adhesive, and chemotactic factor 
for endothelial cells  [31] . Isoda et al.  [32] used a trans-
genic mouse model overexpressing the OPN gene and 
demonstrated that OPN induces both medial thickening 
without injury and neointimal formation after injury sug-
gesting a certain role in the development of vascular re-
modeling after angioplasty in vivo . 
 The reestablishment of an endothelial monolayer is 
important in cases of reconstructive vascular surgery and 
vascular trauma. Our data of the present study are of sig-
nifi cant clinical relevance. The endothelium plays a crit-
ical role in thrombogenicity and vascular tone and de-
layed endothelial healing after injury, such as after surgi-
cal procedures (transplantation, replantation, reconstruc-
tive surgery).  
 Furthermore, osteopontin appears to play a key role in 
the vascular remodeling process following microsurgery. 
Here, we present novel data on the role of osteopontin in 
the process of remodeling. 
 In summary, our study demonstrates that local VEGF 
supplementation represents a very useful method to ac-
celerate rET and vascular healing after microvascular in-
jury and reanastomosis within the vascular wall of the rat 
femoral artery. 
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